Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by STEPHEN G SWISHER and ANNE TSAO.
STEPHEN G SWISHER
Connection Strength
1.060
ANNE TSAO
  1. Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-12.
    View in: PubMed
    Score: 0.181
  2. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2024 Oct 23; 12(10).
    View in: PubMed
    Score: 0.062
  3. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Oct 09.
    View in: PubMed
    Score: 0.062
  4. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 09 09; 402(10405):871-881.
    View in: PubMed
    Score: 0.057
  5. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604.
    View in: PubMed
    Score: 0.056
  6. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 11; 164(5):1327-1337.
    View in: PubMed
    Score: 0.051
  7. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021 08; 9(8).
    View in: PubMed
    Score: 0.050
  8. Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma. Ann Thorac Surg. 2022 01; 113(1):200-208.
    View in: PubMed
    Score: 0.049
  9. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
    View in: PubMed
    Score: 0.048
  10. Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clin Cancer Res. 2020 10 15; 26(20):5477-5486.
    View in: PubMed
    Score: 0.047
  11. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459.
    View in: PubMed
    Score: 0.046
  12. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536.
    View in: PubMed
    Score: 0.045
  13. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer. 2020 07; 21(4):e294-e301.
    View in: PubMed
    Score: 0.045
  14. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 06 20; 37(18):1558-1565.
    View in: PubMed
    Score: 0.043
  15. Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database. J Thorac Dis. 2019 Apr; 11(4):1269-1278.
    View in: PubMed
    Score: 0.042
  16. Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2018 05 01; 53(5):960-966.
    View in: PubMed
    Score: 0.040
  17. Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. J Clin Oncol. 2017 Oct 10; 35(29):3354-3362.
    View in: PubMed
    Score: 0.038
  18. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682.
    View in: PubMed
    Score: 0.036
  19. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg. 2012 Sep; 94(3):914-20.
    View in: PubMed
    Score: 0.027
  20. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007 Nov; 84(5):1685-92; discussion 1692-3.
    View in: PubMed
    Score: 0.019
  21. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg. 2005 Dec; 80(6):1988-92; discussion 1992-3.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.